

Current Effective Date: 12/19/24

Status: Approved

Reviewed by Medical Policy Subcommittee: 2/2/23, 12/19/24

Reviewed Dates: 11/29/2022, 12/12/24

INSTRUCTIONS FOR USE DISCLAIMER:

SummaCare posts policies relating to coverage and medical necessity issues to assist members and providers in administering member benefits. These policies do not constitute a contract or agreement between SummaCare and any member or provider. The policies are guidelines only and are intended to assist members and providers with coverage issues. SummaCare is not a health care provider, does not provide or assist with health care services or treatment, and does not make guarantees as to the effectiveness of treatment administered by providers. The treatment of members is the sole responsibility of the treating provider, who is not an employee of SummaCare, but is an independent contractor in private practice. The policies posted to this site may be updated and are subject to change without prior notice to members or providers.

Medical policies in conjunction with other nationally recognized standards of care are used to make medical coverage decisions.

Screening for Prediction and Prevention Pre-eclampsia Policy

Indication/Usage:

Preeclampsia is a multisystem progressive disorder diagnosed by the new onset of hypertension and proteinuria or the new onset of hypertension and significant end-organ dysfunction with or without proteinuria in the last half of pregnancy or postpartum. Measurement of soluble FMS-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) may be helpful for the diagnosis of preeclampsia. These are angiogenic factors secreted by the placenta and implicated in the pathogenesis of preeclampsia. Further studies are needed to validate the use of these tests and determine the clinical utility.

Medical Indications for Authorization Commercial and Medicare Members

SummaCare considers the following testing for the prediction of preeclampsia experimental and investigational because its effectiveness for these indications has not been established.

- Serum YKL-40 for evaluation of pre-eclampsia
- Ophthalmic artery Doppler
- Preeclampsia Screen|T1
- Serum ischemia-modified albumin biomarker
- PIGF Preeclampsia Screen (a biochemical assay of placental growth factor)

There is currently no NCD or LCD per CMS

CPT code 0243U- Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia.

CPT codes **93886, 93888** transcranial Doppler study of the intracranial arteries

Limitations

Multivariable preeclampsia risk assessment tools have been developed that incorporate maternal serum biomarkers; several of these tools have been commercially but few have been externally validated. Additional testing needs to be done for preeclampsia because its effectiveness has not been established.

Coverage Decisions

Coverage decisions made per CMS Guidelines, Hayes Research and industry standards research

Plans Covered By This Policy

Commercial and Medicare

Considered experimental and investigational for all lines of business

Sources Reviewed

Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Sep. <https://www.ncbi.nlm.nih.gov/books/NBK574449/>

Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Executive Summary: Workshop on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine and the Preeclampsia Foundation. Am J Obstet Gynecol. Sep 2021; 225(3): B2-B7.

Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA. Sep 28 2021; 326(12): 1186-1191.

Allen R, Aquilina J. Prospective observational study to determine the accuracy of first-trimester serum biomarkers and uterine artery Dopplers in combination with maternal characteristics and arteriography for the prediction of women at risk of preeclampsia and other adverse pregnancy outcomes. J Matern Fetal Neonatal Med. 2018; 31(21):2789-2806.

Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: A systematic review. Obstet Gynecol Surv. 2011; 66(4):225-239.

American College of Obstetricians and Gynecologists (ACOG). Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. June 2020

August P, Sibai B. Preeclampsia: Clinical features and diagnosis. In Up-to-date, Post TW (Ed), UpToDate, Waltham, MA. Last updated: Jan 11, 2022.

McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm preeclampsia: the COMPARE study. Ultrasound Obstet Gynecol. 2019 Jan; 53(1):62-67

[Home - Centers for Medicare & Medicaid Services | CMS](#)